69 results
424B4
RNAZ
TransCode Therapeutics Inc
19 Jan 24
Prospectus supplement with pricing info
9:57pm
anticipated;
trials being subjected to fraud or data capture failure or other technical mishaps leading to the invalidation of our trials in whole … , possibly materially.
Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
8-K
EX-10.1
38gk19jetxeuarljr
4 Dec 23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
5:07pm
424B4
2emg2x3m hm
27 Sep 23
Prospectus supplement with pricing info
5:26pm